MarketCap
Facebook
X
Telegram
Evolus Market Cap | EOLS
As of September 14, 2026 Evolus has a market cap of $ 519 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 271 M | 887 M | 838 M | 496 M | 369 M | 228 M | 284 M | 381 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 887 M | 228 M | 469 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M |  USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Lannett Company
LCI
|
23 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
12.8 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
396 B | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
393 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Bausch Health Companies
BHC
|
2.03 B | $ 5.94 | 1.28 % | $ 2.2 B |  Canada |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.78 | 1.38 % | $ 3.35 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
84.8 M | $ 6.53 | 2.19 % | $ 97 M | USA |
 |
Cronos Group
CRON
|
736 M | $ 3.22 | 2.55 % | $ 1.23 B | Canada |
 |
Emergent BioSolutions
EBS
|
452 M | $ 6.39 | 2.4 % | $ 342 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 34.16 | 0.09 % | $ 1.26 B | USA |
 |
Organogenesis Holdings
ORGO
|
337 M | $ 1.48 | 1.01 % | $ 188 M | USA |
 |
Pacira BioSciences
PCRX
|
1.17 B | $ 25.2 | 0.02 % | $ 1.12 B | USA |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 13.98 | 2.23 % | $ 1.94 B | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 7.94 | 0.75 % | $ 286 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 4.5 | 0.11 % | $ 178 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 4.6 | 2.69 % | $ 230 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 9.03 | 3.79 % | $ 790 M | USA |
 |
Sundial Growers
SNDL
|
348 M | $ 1.37 | 1.87 % | $ 354 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
1.85 M | $ 1.29 | 2.29 % | $ 2.17 M | USA |
 |
Tilray
TLRY
|
3.65 B | $ 4.14 | 3.11 % | $ 3.69 B | Canada |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.16 | 0.23 % | $ 25 M | USA |
 |
Veru
VERU
|
84.9 M | $ 2.37 | 0.4 % | $ 34.7 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 16.69 | 1.09 % | $ 19.2 B | USA |
 |
cbdMD
YCBD
|
3.58 M | $ 0.48 | 0.94 % | $ 1.93 M | USA |
 |
PLx Pharma
PLXP
|
119 M | - | -27.8 % | $ 2.56 M | USA |
 |
HEXO Corp.
HEXO
|
276 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Canopy Growth Corporation
CGC
|
292 M | $ 0.94 | 1.32 % | $ 280 M | Canada |
 |
OrganiGram Holdings
OGI
|
151 M | $ 1.08 | 2.38 % | $ 103 M | Canada |
 |
Aurora Cannabis
ACB
|
224 M | $ 3.83 | 2.27 % | $ 210 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | - | - | $ 150 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
187 K | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Tricida
TCDA
|
408 M | - | - | $ 3.25 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |